急性肾损伤生物标记物  

New Biomarkers of Acute Kidney Injury

作　　者：周建芳[1] 杜斌[2] 

机构地区：[1]北京协和医院MICU,100730 [2]中国医学科学院北京协和医学院,100730

出　　处：《麻醉与监护论坛》2011年第3期190-194,共5页Forum of Anesthesia and Monitoring

摘　　要：急性肾损伤（Acute kidney injury，AKI）指各种原因导致的肾功能急剧下降．是临床常见的急重症，可导致病死率增加．住院时间延长。由于目前缺乏早期．特异、无创的标记物，因此尚无法实现AKI的早期发现和早期治疗。目前AKI的诊断主要根据血肌酐的变化。但血肌酐的升高常滞后于肾功能损害，且不能准确反映肾小球滤过率。因此AKI的诊治迫切需要新的AKI生物标记物。随着现代科学技术飞速发展．越来越多的新的生物标记物得以发现并遴选出来。如白介素-18（interleukin－18．IL－18）．肾损伤分子－1（kidney injury molecule－1，KIM－1）．这些新的标记物有望早期诊断AKI并对病情进行分层。本综述将对这些AKI生物标记物的用途、价值进行归纳总结。Acute kidney injury （AKI） refers to the rapid decrease of renal function caused by various kinds of factors. It is a common condition in our clinical work and is associated with increased mortality and prolonged length of hospital stay. However, the paucity of early, predictive, non-invasive biomarkers has impaired our ability to institute potentially effective therapies for AKI in a timely manner. Serum creatinine, the current main diagnostic test for AKI, rises late in AKI pathophysiology and is an inaccurate marker of acute changes in glomerular filtration rate. Therefore, new biomarkers of AKI are needed. Fortunately, the tools of modern science have revealed promising novel biomarkers for AKI, such as interleukin-18（IL-18） and kidney injury molecule-1（KIM-1）. These new biomarkers may be useful for early AKI diagnosis and for AKI stratification. This review will provide a summary of selected biomarkers that may be contributors for AKI.

关 键 词：急性肾损伤 诊断 生物标记物 

分 类 号：R730.43[医药卫生—肿瘤]